Biosensors Market: Focus on Drug Discovery and Development - Distribution by Type of Biosensor (Optical, Electrochemical, Thermal and Others), Type of End User (Academic and Research Institutes and Industry Players) and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    June 2022

  • Pages
    217

  • View Count
    942

Example Insights

Biosensors-Market-Context-thumb Biosensors-Market-List-of-Biosensors-thumb Biosensors-Market-Distribution-by-Type-of-Biosensor-thumb Biosensors-Market-Distribution-by-Company-Size-thumb
Biosensors-Market-Product-Competitiveness-Analysis-thumb Biosensors-Market-Brand-Positioning-Matrix-thumb Biosensors-Market-Distribution-of-Amount-Invested-thumb Biosensors-Market-Distribution-by-Year-of-Publication-thumb
Biosensors-Market-Distribution-by-Type-of-Event-thumb Biosensors-Market-Distribution-by-Type-of-Patent-thumb Biosensors-Market-Distribution-by-Geography-thumb  

Overview

The drug discovery process, which involves the identification of a relevant biological target and a corresponding pharmacological lead, is deemed crucial to the clinical success of a drug candidate. However, considering the growing complexity of modern pharmacology, the discovery of viable therapeutic candidates is very demanding, both in terms of time and capital investment. In fact, as per estimates, a therapeutic drug takes around 10 to 15 years and an average investment of USD 1 to 2 billion, to traverse from the bench to the market. It is also a well-known fact that only a small proportion of pharmacological leads, identified during the discovery stages, are actually translated into viable product candidates for clinical studies. Experts believe that close to 90% of the product candidates fail to make it past the clinical stage of development. The high attrition rate has long been attributed to the legacy drug discovery process, which is more of a trial-and-error paradigm. In attempts to address the concerns associated with rising capital requirements in drug discovery and prevent late stage failure of drug development programs, stakeholders in the pharmaceutical industry are currently exploring the implementation of biosensors (an analytical device consisting of a biological component, such as antibodies, enzymes, cells, lipids and oligonucleotides, and a physical transducer) to enable the effective screening of lead drug candidates from thousands of hits. Further, biosensors can be used for routine analysis of known, as well as unknown, analytes.

At present, various types of biosensors, including optical biosensors, electrochemical biosensors, thermal biosensors and others, are being deployed across different steps of drug discovery, such as disease modelling, target identification / validation, lead identification, lead optimization and other applications. It is worth mentioning that the use of biosensing technologies in drug discovery operations is expected to improve the overall R&D productivity by enabling accurate screening and identification of lead drug compounds. Currently, more than 80 biosensors are available in the market / being developed by various industry stakeholders for drug discovery and development purposes. Further, over USD 1.2 billion has been invested in this market by both private and public sector investors, in the last five years. Interestingly, close to 50% of the aforementioned amount was invested in the last two years, reflecting the increasing interest of stakeholders in this domain. It is also worth highlighting that over 370 patents related to biosensors in drug discovery have been filed / granted, highlighting the continuous pace of innovation in this field. Considering the active initiatives being undertaken by players in this domain, we are led to believe that the opportunity for stakeholders in this niche, but upcoming, industry is likely to grow at a commendable pace in the foreseen future.

Scope of the Report

The “Biosensors Market: Focus on Drug Discovery and Development - Distribution by Type of Biosensor (Optical, Electrochemical, Thermal and Others), Type of End User (Academic and Research Institutes and Industry Players) and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of biosensors in drug discovery, over the next 13 years. The study features an in-depth analysis of key drivers and trends related to this domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of biosensors in drug discovery, along with information on several relevant parameters, such as type of biosensor (optical biosensors, electrochemical biosensors, quartz crystal microbalance biosensors, thermal biosensors and magneto-electric biosensors), bioreceptor used (cells, proteins, lipids, enzymes, antibodies and undisclosed), drug discovery step(s) supported (disease modelling, target identification / validation, lead identification, lead optimization, and drug discovery (unspecified)), other applications (ADME assays, toxicity assays, cytotoxicity assays, cell analysis, drug characterization / validation assays and other assays), type of analyte analyzed (small molecules, cell / tissues, protein / peptides, antibodies, nucleotides, viruses, blood products, enzymes, biologics (unspecified) and others), type of carrier plate format (microplate-based sensor, flow through the sensor, chip-based static array sensor, polymerase chain reaction (PCR) format plates-based sensor and undisclosed), sample capacity (less than 96, 96 to 384, 385 to 1536, more than 1536 and undisclosed), sample volume (1 to 50µl, 51 to 100 µl, 101 to 200 µl, more than 200 µl and undisclosed), type of detection (label-free and real-time) and type of system (automatic, semi-automatic and undisclosed). In addition, the chapter features analysis related to biosensor developers based on multiple parameters, such as their year of establishment, company size, location of headquarters and leading players (in terms of number of biosensors developed). 
  • A product competitiveness analysis of biosensors used for drug discovery purposes based on various relevant parameters, namely supplier power (in terms of the experience of the developer) and product competitiveness (in terms of type of biosensor, bioreceptor used, drug discovery step(s) supported, other application(s), type of analyte(s) analyzed, type of carrier plate, sample capacity, type of detection, and type of system used).
  • Elaborate profiles of prominent players developing biosensors for drug discovery applications. Each profile features a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook.
  • An elaborate brand positioning analysis of leading industry players (shortlisted on the basis of year of establishment, number of biosensors developed and company size), highlighting the current perceptions regarding their proprietary brands, across biosensors in drug discovery.
  • An analysis of investments that have been made into companies developing biosensors for drug discovery applications, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing. The investment instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, most active players (in terms of number of funding instances) and type of investor.
  • A detailed review of over 333 peer-reviewed, scientific articles related to research on biosensors in drug discovery on the basis of several relevant parameters, such as year of publication, type of publication, emerging focus areas, most active publishers, most active affiliated institutes and geography. The chapter also highlights the top journals, in terms of number of articles published and impact factor.
  • A detailed analysis of the global events attended by participants, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, and affiliated organizations of participant. The chapter also highlights the geographical mapping of upcoming events.
  • An in-depth analysis of various patents that have been filed / granted related to biosensors in drug discovery, during the period 2018-2022, taking into consideration parameters, such as publication year, geographical region, CPC symbols, patent focus areas, type of applicant, detailed valuation analysis and leading players (in terms of size of intellectual property portfolio).

One of the key objectives of the report was to evaluate the current opportunity and future potential associated with biosensors in drug discovery, over the coming 13 years. We have provided informed estimates of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as [A] type of biosensor (optical, electrochemical, thermal and others), [B] type of end user (academic and research institutes, and industry players) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Bill Rader (Chief Executive Officer, Efferent Labs), 
  • Anne Marie Quinn (Chief Executive Officer, Montana Molecular)
  • Laurent Sabbagh (Associate Director R&D and Head of Biology, Domain Therapeutics Research)

Key Questions Answered

  • Who are the key players engaged in the biosensors in drug discovery market?
  • What is the relative competitiveness of different biosensors being developed for drug discovery applications?
  • What are the key agenda items being discussed in various global events / conferences related to biosensors in drug discovery?
  • What is the focus area of the ongoing research activity related to biosensors in drug discovery?
  • How is the intellectual property landscape for biosensors in drug discovery likely to evolve in the foreseen future?
  • What are the factors that are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our report. It offers a high-level view of the current state of biosensors in drug discovery market and its likely evolution in the short term, mid-term and long term.

Chapter 3 provides a general overview of biosensors and its different components, including analyte, bioreceptor, transducer, electronics and display. Additionally, it highlights different types of biosensors, along with their applications in drug discovery. Further, the chapter includes information on the challenges associated with use of biosensors in this domain. 

Chapter 4 provides a detailed review of the current market landscape of biosensors in drug discovery, featuring information on the type of biosensor (optical biosensors, electrochemical biosensors, quartz crystal microbalance biosensors, thermal biosensors and magneto-electric biosensors), bioreceptor used (cells, proteins, lipids, enzymes, antibodies and undisclosed), drug discovery step(s) supported (disease modelling, target identification / validation, lead identification, lead optimization, and drug discovery (unspecified)), other applications (ADME assays, toxicity assays, cytotoxicity assays, cell analysis, drug characterization / validation assays and other assays), type of analyte analyzed (small molecules, cell / tissues, protein / peptides, antibodies, nucleotides, viruses, blood products, enzymes, biologics (unspecified) and others), type of carrier plate format (microplate-based sensor, flow through the sensor, chip-based static array sensor, polymerase chain reaction (PCR) format plates-based sensor and undisclosed), sample capacity (less than 96, 96 to 384, 385 to 1536, more than 1,536 and undisclosed), sample volume (1 to 50µl, 51 to 100 µl, 101 to 200 µl, more than 200 µl and undisclosed), type of detection (label-free and real-time) and type of systems (automatic, semi-automatic and undisclosed). In addition, the chapter features analysis related to biosensor developers based on multiple parameters, such as their year of establishment, company size, location of headquarters and leading players (in terms of number of biosensors developed). 

Chapter 5 presents a detailed product competitiveness analysis of biosensors in drug discovery, based on various relevant parameters, namely supplier power (based on the experience of the developer) and product competitiveness (based on various parameters, including type of biosensor, bioreceptor used, drug discovery step(s) supported, other application(s), type of analyte(s) analyzed, type of carrier plate, sample capacity, type of detection, and type of system used). 

Chapter 6 features detailed profiles of the prominent players offering biosensors for drug discovery applications. Each profile features a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook.

Chapter 7 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment, number of biosensors developed and company size), highlighting the current perceptions regarding their proprietary brands across biosensors in drug discovery.

Chapter 8 provides details on the various investments that have been made into companies developing biosensors for drug discovery applications, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing. The investment instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, most active players (in terms of number of funding instances and amount) and type of investor.

Chapter 9 features a detailed review of peer-reviewed, scientific articles related to research on biosensors in drug discovery, on the basis of several relevant parameters, such as year of publication, type of publication, emerging focus areas, most active publisher, most active affiliated institutes and geography. The chapter also highlights the top journals (in terms of number of articles published and impact factor).

Chapter 10 features an analysis of the global events attended by the participants, based on several parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated organizations of participant. The chapter also highlights the geographical mapping of upcoming events.

Chapter 11 provides an insightful analysis of the patents filed / granted for biosensors used for drug discovery during the period between 2018 and 2022 taking into consideration several relevant parameters, such as type of patent, publication year, application year, geographical location, Cooperative Patent Classification (CPC) symbols, emerging focus area, leading industry and non-industry players (on the basis of number of patents) and individual patent assignees (in terms of size of intellectual property portfolio), patent characteristics and age of patents. The chapter also includes an insightful valuation analysis.

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of the biosensors in drug discovery market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of biosensor (optical, electrochemical, thermal and others), [B] type of end user (academic and research institutes, and industry players) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world). 

Chapter 13 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Bill Rader (Chief Executive Officer, Efferent Labs), Anne Marie Quinn (Chief Executive Officer, Montana Molecular), and Laurent Sabbagh (Associate Director R&D and Head of Biology, Domain Therapeutics). 

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. An Overview of Biosensors
3.3. Components of Biosensors
3.4. Types of Biosensors
3.5. Applications of Biosensors in Drug Discovery
3.6. Challenges Associated with Use of Biosensors in Drug Discovery
3.7. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biosensors in Drug Discovery: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Most Active Players: Analysis by Number of Biosensors Developed
4.2.5. Analysis by Type of Biosensor
4.2.6. Analysis by Type of Bioreceptor Used
4.2.7. Analysis by Type of Biosensor and Type of Bioreceptor Used
4.2.8. Analysis by Drug Discovery Step(s) Supported
4.2.9. Analysis by Other Applications Supported
4.2.10. Analysis by Type of Analyte
4.2.11. Analysis by Carrier Plate Format
4.2.12. Analysis by Type of Biosensor and Carrier Plate Format
4.2.13. Analysis by Sample Capacity
4.2.14. Analysis by Sample Volume
4.2.15. Analysis by Type of Detection Method Employed
4.2.16. Analysis by Type of System

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.3. Product Competitiveness Analysis: Biosensors in Drug Discovery

6. COMPANY PROFILES: BIOSENSORS DEVELOPERS FOR DRUG DISCOVERY APPLICATIONS
6.1. Chapter Overview
6.2. Agilent Technologies
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Axion Biosystems
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. BioNavigations
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook

6.5. Creoptix
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. Cytiva
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook

6.7. Dynamic Biosensors
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook

6.8. Malvern Panalytical
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3. Recent Developments and Future Outlook

6.9. Microvacuum
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook

6.10. Sartorius
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook

6.11. Tempo Bioscience
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook

7. BRAND POSITIONING ANALYSIS
7.1. Chapter Overview
7.2 Key Parameters
7.3. Methodology
7.4. Biosensor Developers for Drug Discovery Applications
7.4.1. Brand Positioning Matrix: Agilent Technologies
7.4.2. Brand Positioning Matrix: Cytiva
7.4.3. Brand Positioning Matrix: Sartorius
7.4.4. Brand Positioning Matrix: Malvern Panalytical

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. Biosensors in Drug Discovery: Funding and Investments
8.3.1. Analysis of Funding Instances by Year
8.3.2. Analysis of Amount Invested by Year
8.3.3. Analysis of Funding Instances by Type of Funding
8.3.4. Analysis of Amount Invested by Type of Funding
8.3.5. Analysis of Funding Instances by Type of Biosensor
8.3.6. Most Active Players: Analysis by Number of Funding Instances
8.3.7. Most Active Players: Analysis by Amount Invested
8.3.8. Most Active Investors: Analysis by Number of Funding Instances
8.3.9. Analysis of Amount Invested by Geography
8.3.9.1. Analysis by Region
8.3.9.2. Analysis by Country

9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Biosensors in Drug Discovery: Publication Analysis
9.3.1. Analysis by Year of Publication
9.3.2. Analysis by Type of Publication
9.3.3. Most Popular Journals: Analysis by Number of Publications
9.3.4. Most Popular Journals: Analysis by Impact Factor
9.3.5. Analysis by Most Popular Keywords
9.3.6. Most Active Publisher: Analysis by Number of Publications
9.3.7. Most Active Affiliated Institutes: Analysis by Number of Publications
9.3.8. Analysis by Geography

10. GLOBAL EVENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. List of Global Events Related to Biosensors in Drug Discovery
10.3.1. Analysis by Year of Event
10.3.2. Analysis by Event Platform
10.3.3. Analysis by Type of Event
10.3.4. Analysis by Location of Event
10.3.5. Analysis by Evolutionary Trends in Event Agendas / Key Focus Areas
10.3.6. Most Active Organizers: Analysis by Number of Events
10.3.7. Analysis by Designation of Participants
10.3.8. Analysis by Affiliated Department of Participants
10.3.9. Analysis by Geography of Upcoming Events

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Biosensors in Drug Discovery: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Geography
11.3.3. Analysis by CPC Symbols
11.3.4. Analysis by Emerging Focus Areas
11.3.5. Analysis by Patent Age
11.3.6. Analysis by Type of Applicant
11.3.7. Leading Industry Players: Analysis by Number of Patents
11.3.8. Leading Non-Industry Players: Analysis by Number of Patents
11.3.9. Leading Individual Assignees: Analysis by Number of Patents

11.4. Biosensors in Drug Discovery: Patent Valuation
11.5. Leading Patents: Analysis by Number of Citations

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Biosensors in Drug Discovery Market, 2022-2035

12.3.1. Biosensors in Drug Discovery Market: Distribution by Type of Biosensor, 2022 and 2035
12.3.1.1. Optical Biosensors in Drug Discovery Market, 2022-2035
12.3.1.2. Electrochemical Biosensors in Drug Discovery Market, 2022-2035
12.3.1.3. Thermal Biosensors in Drug Discovery Market, 2022-2035
12.3.1.4. Other Biosensors in Drug Discovery Market, 2022-2035

12.3.2. Biosensor in Drug Discovery Market: Distribution by Type of End User, 2022 and 2035
12.3.2.1. Biosensor in Drug Discovery Market for Academic and Research Institutes, 2022-2035
12.3.2.2. Biosensor in Drug Discovery Market for Industry Players, 2022-2035

12.3.3. Biosensor in Drug Discovery Market: Distribution by Region, 2022 and 2035
12.3.3.1. Biosensor in Drug Discovery Market in North America, 2022-2035
13.3.3.2. Biosensor in Drug Discovery Market in Europe, 2022-2035
12.3.3.3. Biosensor in Drug Discovery Market in Asia Pacific, 2022-2035
12.3.3.4. Biosensor in Drug Discovery Market in Latin America, 2022-2035
12.3.3.5. Biosensor in Drug Discovery Market in Middle East and North Africa, 2022-2035
12.3.3.6. Biosensor in Drug Discovery Market in Rest of the World, 2022-2035

13. CONCLUDING REMARKS

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Efferent Labs
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Bill Rader (Chief Executive Officer)

14.3. Montana Molecular
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Anne Marie Quinn (Chief Executive Officer)

14.4. Domain Therapeutics
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Laurent Sabbagh (Associate Director R&D, Head of Biology)

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Funding and Investments
Figure 2.3 Executive Summary: Publication Analysis
Figure 2.4 Executive Summary: Global Event Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Components of Biosensors
Figure 3.2 Electrochemical Biosensor
Figure 3.3 Thermal Biosensor
Figure 3.4 Optical Biosensor
Figure 3.5 Piezo-electric Biosensor
Figure 3.4 Resonant Biosensor
Figure 4.1 Biosensor Developers for Drug Discovery Applications: Distribution by Year of Establishment
Figure 4.2 Biosensor Developers for Drug Discovery Applications: Distribution by Company Size
Figure 4.3 Biosensor Developers for Drug Discovery Applications: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Biosensor Developers for Drug Discovery Applications: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Biosensor Developers for Drug Discovery Applications: Distribution by Location of Headquarters and Company Size
Figure 4.6 Most Active Players: Distribution by Number of Biosensors Developed
Figure 4.7 Biosensors in Drug Discovery: Distribution by Type of Biosensor
Figure 4.8 Biosensors in Drug Discovery: Distribution by Type of Bioreceptor Used
Figure 4.9 Biosensors in Drug Discovery: Distribution by Type of Biosensor and Type of Bioreceptor Used
Figure 4.10 Biosensors in Drug Discovery: Distribution by Drug Discovery Step(s) Supported
Figure 4.11 Biosensors in Drug Discovery: Distribution by Other Applications Supported
Figure 4.12 Biosensors in Drug Discovery: Distribution by Type of Analyte
Figure 4.13 Biosensors in Drug Discovery: Distribution by Carrier Plate Format
Figure 4.14 Biosensors in Drug Discovery: Distribution by Type of Biosensor and Carrier Plate Format
Figure 4.15 Biosensors in Drug Discovery: Distribution by Sample Capacity
Figure 4.16 Biosensors in Drug Discovery: Distribution by Sample Volume
Figure 4.17 Biosensors in Drug Discovery: Distribution by Type of Detection Method Employed
Figure 4.18 Biosensors in Drug Discovery: Distribution by Type of System
Figure 5.1 Product Competitiveness Analysis: Dot Plot Analysis
Figure 5.2 Product Competitiveness Analysis: Biosensors in Drug Discovery
Figure 7.1 Biosensor Developers for Drug Discovery Applications: Brand Positioning Matrix
Figure 7.2 Brand Positioning Matrix: Agilent Technologies
Figure 7.3 Brand Positioning Matrix: Cytiva
Figure 7.4 Brand Positioning Matrix: Sartorius
Figure 7.5 Brand Positioning Matrix: Malvern Panalytical
Figure 8.1 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2018-2022
Figure 8.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, 2018-2022 (USD Million)
Figure 8.3 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Figure 8.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 8.5 Funding and Investment Analysis: Distribution of Funding Instances by Type of Biosensor
Figure 8.6 Most Active Players: Distribution by Number of Funding Instances
Figure 8.7 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 8.8 Most Active Investors: Distribution by Number of Funding Instances
Figure 8.9 Funding and Investment Analysis: Distribution of Amount Invested by Region (USD Million)
Figure 8.10 Funding and Investment Analysis: Distribution of Amount Invested by Country (USD Million)
Figure 9.1 Publication Analysis: Distribution by Year of Publication
Figure 9.2 Publication Analysis: Distribution by Type of Publication
Figure 9.3 Most Popular Journals: Distribution by Number of Publications
Figure 9.4 Most Popular Journals: Distribution by Impact Factor
Figure 9.5 Publication Analysis: Most Popular Keywords
Figure 9.6 Most Active Publisher: Distribution by Number of Publications
Figure 9.7 Most Active Affiliated Institutes: Distribution by Number of Publications
Figure 9.8 Publication Analysis: Distribution by Geography
Figure 10.1 Global Event Analysis: Cumulative Quarterly Trend
Figure 10.2 Global Event Analysis: Distribution by Event Platform
Figure 10.3 Global Event Analysis: Distribution by Type of Event
Figure 10.4 Global Event Analysis: Distribution by Location of Event
Figure 10.5 Global Event Analysis: Distribution by Evolutionary Trends in Event Agenda / Key Focus Area
Figure 10.6 Most Active Organizers: Distribution by Number of Events
Figure 10.7 Global Event Analysis: Distribution by Designation of Participants
Figure 10.8 Global Event Analysis: Distribution by Affiliated Department of Participants
Figure 10.9 Global Event Analysis: Geography of Upcoming Events
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Distribution by Patent Publication Year
Figure 11.3 Patent Analysis: Distribution by Geography
Figure 11.4 Patent Analysis: Distribution by CPC Symbols
Figure 11.5 Patent Analysis: Emerging Focus Areas
Figure 11.6 Patent Analysis: Distribution by Patents Age
Figure 11.7 Patent Analysis: Distribution by Type of Applicant
Figure 11.8 Leading Industry Players: Distribution by Number of Patents
Figure 11.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.10 Leading Individual Assignees: Distribution by Number of Patents
Figure 11.11 Biosensors in Drug Discovery: Patent Valuation Analysis
Figure 12.1 Global Biosensors in Drug Discovery Market, 2022-2035 (USD Billion)
Figure 12.2 Biosensors in Drug Discovery Market: Likely Growth Scenarios
Figure 12.3 Biosensors in Drug Discovery Market: Distribution by Type of Biosensor, 2022 and 2035 (USD Billion)
Figure 12.4 Optical Biosensors in Drug Discovery Market, 2022-2035 (USD Billion)
Figure 12.5 Electrochemical Biosensors in Drug Discovery Market, 2022-2035 (USD Billion)
Figure 12.6 Thermal Biosensors in Drug Discovery Market, 2022-2035 (USD Billion)
Figure 12.7 Other Biosensors in Drug Discovery Market, 2022-2035 (USD Billion)
Figure 12.8 Biosensors in Drug Discovery Market: Distribution by Type of End User, 2022 and 2035
Figure 12.9 Biosensors in Drug Discovery Market for Academic and Research Institutes, 2022-2035 (USD Billion)
Figure 12.10 Biosensors in Drug Discovery Market for Industry Players, 2022-2035 (USD Billion)
Figure 12.11 Biosensors in Drug Discovery Market: Distribution by Region, 2022 and 2035
Figure 12.12 Biosensors in Drug Discovery Market in North America, 2022-2035 (USD Billion)
Figure 12.13 Biosensors in Drug Discovery Market in Europe, 2022-2035 (USD Billion)
Figure 12.14 Biosensors in Drug Discovery Market in Asia Pacific, 2022-2035 (USD Billion)
Figure 12.15 Biosensors in Drug Discovery Market in Latin America, 2022-2035 (USD Billion)
Figure 12.16 Biosensors in Drug Discovery Market in Middle East and North Africa, 2022-2035 (USD Billion)
Figure 12.17 Biosensors in Drug Discovery Market in Rest of the World, 2022-2035 (USD Billion)
Figure 13.1 Concluding Remarks: Market Landscape
Figure 13.2 Concluding Remarks: Funding and Investments Analysis
Figure 13.3 Concluding Remarks: Publication Analysis
Figure 13.4 Concluding Remarks: Global Event Analysis
Figure 13.5 Concluding Remarks: Patent Analysis
Figure 13.6 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 4.1 Biosensors in Drug Discovery: List of Companies
Table 4.2 Biosensors in Drug Discovery: Information on Type of Biosensor, Bioreceptor used, Drug Discovery Step(s) and Other Applications Supported
Table 4.3 Biosensors in Drug Discovery: Information on Type of Analyte
Table 4.4 Biosensors in Drug Discovery: Information on Carrier Plate Format, Sample Capacity, Sample Volume, Type of Detection Method Employed and Type of System
Table 6.1 Leading Biosensor Developers
Table 6.2 Agilent Technologies: Company Overview
Table 6.3 Agilent Technologies: Product Portfolio
Table 6.4 Agilent Technologies: Recent Developments and Future Outlook
Table 6.5 Axion Biosystems: Company Overview
Table 6.6 Axion Biosystems: Product Portfolio
Table 6.7 BioNavigations: Company Overview
Table 6.8 BioNavigations: Product Portfolio
Table 6.9 Creoptix: Company Overview
Table 6.10 Creoptix: Product Portfolio
Table 6.11 Creoptix: Recent Developments and Future Outlook
Table 6.12 Cytiva: Company Overview
Table 6.13 Cytiva: Product Portfolio
Table 6.14 Cytiva: Recent Developments and Future Outlook
Table 6.15 Dynamic Biosensors: Company Overview
Table 6.16 Dynamic Biosensors: Product Portfolio
Table 6.17 Dynamic Biosensors: Recent Developments and Future Outlook
Table 6.18 Malvern Panalytical: Company Overview
Table 6.19 Malvern Panalytical: Product Portfolio
Table 6.20 Malvern Panalytical: Recent Developments and Future Outlook
Table 6.21 Microvacuum: Company Overview
Table 6.22 Microvacuum: Product Portfolio
Table 6.23 Sartorius: Company Overview
Table 6.24 Sartorius: Product Portfolio
Table 6.25 Sartorius: Recent Developments and Future Outlook
Table 6.26 Tempo Bioscience: Company Overview
Table 6.27 Tempo Bioscience: Product Portfolio
Table 8.1 Biosensors in Drug Discovery: List of Funding and Investments, 2018-2022
Table 9.1 Biosensors in Drug Discovery: List of Recent Publications, 2018-2022
Table 10.1 Biosensors in Drug Discovery: List of Global Events, 2021-H2 2023
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.5 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
Table 11.6 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
Table 14.1 Efferent Labs: Company Snapshot
Table 14.2 Montana Molecular: Company Snapshot
Table 14.2 Domain Therapeutics: Company Snapshot
Table 15.1 Biosensor Developers for Drug Discovery Applications: Distribution by Year of Establishment
Table 15.2 Biosensor Developers for Drug Discovery Applications: Distribution by Company Size
Table 15.3 Biosensor Developers for Drug Discovery Applications: Distribution by Location of Headquarters (Region-wise)
Table 15.4 Biosensor Developers for Drug Discovery Applications: Distribution by Location of Headquarters (Country-wise)
Table 15.5 Biosensor Developers for Drug Discovery Applications: Distribution by Location of Headquarters and Company Size
Table 15.6 Most Active Players: Distribution by Number of Biosensors Developed
Table 15.7 Biosensors in Drug Discovery: Distribution by Type of Biosensor
Table 15.8 Biosensors in Drug Discovery: Distribution by Type of Bioreceptor Used
Table 15.9 Biosensors in Drug Discovery: Distribution by Type of Biosensor and Type of Bioreceptor Used
Table 15.10 Biosensors in Drug Discovery: Distribution by Drug Discovery Step(s) Supported
Table 15.11 Biosensors in Drug Discovery: Distribution by Other Applications Supported
Table 15.12 Biosensors in Drug Discovery: Distribution by Type of Analyte
Table 15.13 Biosensors in Drug Discovery: Distribution by Carrier Plate Format
Table 15.14 Biosensors in Drug Discovery: Distribution by Type of Biosensor and Carrier Plate Format
Table 15.15 Biosensors in Drug Discovery: Distribution by Sample Capacity
Table 15.16 Biosensors in Drug Discovery: Distribution by Sample Volume
Table 15.17 Biosensors in Drug Discovery: Distribution by Type of Detection Method Employed
Table 15.18 Biosensors in Drug Discovery: Distribution by Type of System
Table 15.19 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2018-2022
Table 15.20 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, 2018-2022 (USD Million)
Table 15.21 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Table 15.22 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 15.23 Funding and Investment Analysis: Distribution of Funding Instances by Type of Biosensor
Table 15.24 Most Active Players: Distribution by Number of Funding Instances
Table 15.25 Most Active Players: Distribution by Amount Invested (USD Million)
Table 15.26 Most Active Investors: Distribution by Number of Funding Instances
Table 15.27 Funding and Investment Analysis: Distribution of Amount Invested by Region (USD Million)
Table 15.28 Funding and Investment Analysis: Distribution of Amount Invested by Country (USD Million)
Table 15.29 Publication Analysis: Distribution by Year of Publication
Table 15.30 Publication Analysis: Distribution by Type of Publication
Table 15.31 Most Popular Journals: Distribution by Number of Publications
Table 15.32 Most Popular Journals: Distribution by Impact Factor
Table 15.33 Publication Analysis: Most Popular Keywords
Table 15.34 Most Active Publisher: Distribution by Number of Publications
Table 15.35 Most Active Affiliated Institutes: Distribution by Number of Publications
Table 15.36 Publication Analysis: Distribution by Geography
Table 15.37 Global Event Analysis: Cumulative Quarterly Trend
Table 15.38 Global Event Analysis: Distribution by Event Platform
Table 15.39 Global Event Analysis: Distribution by Type of Event
Table 15.40 Global Event Analysis: Distribution by Location of Event
Table 15.41 Most Active Organizers: Distribution by Number of Events
Table 15.42 Global Event Analysis: Distribution by Designation of Participants
Table 15.43 Global Event Analysis: Distribution by Affiliated Department of Participants
Table 15.44 Global Event Analysis: Geographical Mapping of Upcoming Events
Table 15.45 Patent Analysis: Distribution by Type of Patent
Table 15.46 Patent Analysis: Distribution by Patent Publication Year
Table 15.47 Patent Analysis: Distribution by Geography
Table 15.48 Patent Analysis: Distribution by CPC Symbols
Table 15.49 Patent Analysis: Distribution by Patents Age
Table 15.50 Patent Analysis: Distribution by Type of Applicant
Table 15.51 Leading Industry Players: Distribution by Number of Patents
Table 15.52 Leading Non-Industry Players: Distribution by Number of Patents
Table 15.53 Leading Individual Assignees: Distribution by Number of Patents
Table 15.54 Biosensors in Drug Discovery: Patent Valuation Analysis
Table 15.55 Global Biosensors in Drug Discovery Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.56 Biosensors in Drug Discovery Market: Distribution by Type of Biosensor, 2022 and 2035
Table 15.57 Optical Biosensors in Drug Discovery Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.58 Electrochemical Biosensors in Drug Discovery Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.59 Thermal Biosensors in Drug Discovery Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.60 Other Biosensors in Drug Discovery Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.61 Biosensors in Drug Discovery Market: Distribution by Type of End User, 2022 and 2035
Table 15.62 Biosensors in Drug Discovery Market for Academic and Research Institutions, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.63 Biosensors in Drug Discovery Market for Industry Players, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.64 Biosensors in Drug Discovery Market: Distribution by Region, 2022 and 2035
Table 15.65 Biosensors in Drug Discovery Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.66 Biosensors in Drug Discovery Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.67 Biosensors in Drug Discovery Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.68 Biosensors in Drug Discovery Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.69 Biosensors in Drug Discovery Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.70 Biosensors in Drug Discovery Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 3E Bioventures Capital
  2. ACEA Biosciences
  3. Agency for Science, Technology and Research (A*STAR) 
  4. Agilent Technologies
  5. Agilome
  6. Alexandria Venture Investments
  7. Applied BioPhysics
  8. Aromyx
  9. ARTIS Ventures
  10. Attana
  11. Axion BioSystems
  12. Ballast Point Ventures
  13. Beactica Therapeutics
  14. BioLoomics
  15. BioNavigations
  16. BiOptix Analytical 
  17. Biosens Labs
  18. Biosensing Instrument
  19. Boston University
  20. Bruker
  21. Cardea Bio
  22. Carterra
  23. Catalan Institute of Nanoscience and Nanotechnology (ICN2)
  24. Chinese Academy of Sciences
  25. Comerica Bank's Technology & Life Sciences Division
  26. Columbia University
  27. Creoptix (Acquired by Malvern Panalytical)
  28. Cytiva
  29. Delix therapeutics
  30. Domain Therapeutics
  31. Dresden University of Technology (TUD)
  32. Dynamic Biosensors
  33. Swiss Federal Institute of Technology Lausanne
  34. Efferent Labs
  35. Eindhoven University of Technology
  36. Falcon III Ventures
  37. Garage Capital
  38. Gator Bio
  39. GE Healthcare
  40. Genapsys
  41. Harvard College
  42. Helmholtz-Zentrum Dresden-Rossendorf
  43. HORIBA
  44. High-Tech Gründerfonds
  45. IBIS Technologies
  46. IBM
  47. Indian Institute of Technology, Madras
  48. InterAx Biotech
  49. International Iberian Nanotechnology Laboratory (INL)
  50. Interuniversity Microelectronics Centre (IMEC)
  51. Invitrometrix
  52. Karlsruhe Institute of Technology
  53. Laurier Startup Fund 
  54. Lifespan Investments
  55. lino Biotech
  56. MagArray
  57. Malvern Panalytical
  58. MaRS Investment Accelerator Fund
  59. MicroVacuum
  60. Molecular Devices
  61. Monash University
  62. Montana Molecular
  63. National Center for Scientific Research (CNRS)
  64. National Institute on Drug Abuse
  65. National Nanotechnology Coordination Office (NNCO)
  66. Nicoya Lifesciences
  67. Ningbo University
  68. NRI R&D Patent Licensing
  69. OMX Ventures
  70. Osaka University
  71. Photon Fund
  72. Photonic Pharma
  73. Plexense
  74. Provigate
  75. RA Capital Management
  76. Roche
  77. Roche Venture Fund
  78. Roswell Biotechnologies
  79. Sapidyne Instruments
  80. Sartorius
  81. Seoul National University
  82. Serra Ventures
  83. Seventure Partners
  84. Sorbonne Université
  85. Stanford University
  86. Swisscanto
  87. Table Mountain Capital
  88. Taihill Venture
  89. Taiwan Semiconductor Manufacturing (TMSC)
  90. Telegraph Hill Partners
  91. Tempo Bioscience
  92. National Institutes of Health
  93. Tsingyuan Ventures
  94. US Department of Homeland Security
  95. Umm Al-Qura University
  96. University of La Sabana
  97. University of Auckland
  98. University of Bologna
  99. University of California
  100. University of Chicago
  101. Johns Hopkins University
  102. University of Malaya
  103. University of Medicine and Pharmacy Craiova
  104. University of Minnesota
  105. University of Montreal
  106. University of Oxford
  107. University of Porto
  108. University of Strathclyde
  109. Vanderbilt University
  110. University of Waterloo Student Venture Fund
  111. Warsaw University of Technology
  112. Waters Corporation
  113. Whitecap Venture Partners

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com